drugset / Trial / NCT07152236
Clinical Study on the Safety and Efficacy of B7H3 CAR T Cells in Patients With B7H3 Positive Solid Tumors
Withdrawn
Guangzhou Bio-gene Technology Co., Ltd
NaSingle-groupOpen-labelTreatment
Summary
This single-arm, single-center investigator-initiated trial (IIT) evaluates the safety, efficacy, and pharmacodynamic (PD)/pharmacokinetic (PK) profiles of CAR-T cells in patients with advanced solid tumors. Eligible subjects are followed until 12 months after infusion or until meeting treatment withdrawal criteria, whichever occurs first.
Timeline
- Start
- 2025-08-31
- Primary completion
- 2026-03-02
- Completion
- 2026-03-02
Outcome
Outcome not reported
Stopped (Business): “Due to corporate strategic adjustment.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CAR-T | Cell therapy | 3e+06 cells/kg | Intravenous |
| Subject | CAR-T | Cell therapy | 1e+07 cells/kg | Intravenous |